CD163 and diffuse large B-cell lymphoma: Some published studies evaluating TAMs in DLBCL have demonstrated that a higher CD68 or CD68/CD163 ratio was associated with M1 presentation and a favorable prognosis among DLBCL patients who received rituximab combined immunochemotherapy (14).